Persister Bacteria Killing Compounds for Dormant Cell Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against persister cells and dormant 'viable but non-culturable' (VBNC) cells, leading to recalcitrant bacterial infections.
Innovation Solution
Compounds such as [(5-nitro-3-phenyl-1H-indol-2-yl)methyl]amine hydrochloride (NPIMA) and 2-{[2-(4-bromophenyl)-2-oxoethyl]thio}-3-ethyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one (BPOET) are used to kill, reduce, or eradicate persister cells and VBNC cells in bacterial populations, including pathogenic bacteria like Escherichia spp., Staphylococcus spp., and Pseudomonas spp.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then actively growing cells are killed, but persister cells and VBNC cells survive and reconstitute infections
Solution Approach 1:
The patent employs compounds that induce metabolic activity in dormant persister and VBNC cells, changing their physiological state from dormant to metabolically active, thereby making them susceptible to antibiotic killing. This parameter change in bacterial metabolic state resolves the contradiction by enabling antibiotics to effectively target previously resistant cell types.
2Productivity
If antibiotics are used to eliminate bacteria, then most bacteria are killed, but persister cells survive due to metabolic inactivity
Solution Approach 1:
The patent applies compounds that preemptively activate metabolism in dormant persister and VBNC cells before antibiotic administration. This preliminary metabolic activation ensures that when antibiotics are subsequently applied, all bacterial cells including previously dormant ones are in a susceptible state, achieving complete eradication without compromising clearance rate.
3Reliability
If new compounds are developed to target persister cells, then antibiotic effectiveness against dormant cells improves, but the complexity of treatment regimens increases
Solution Approach 1:
The patent combines compounds that activate bacterial metabolism with existing antibiotics in single compositions. This merging of functions into unified treatment regimens maintains improved efficacy against persister cells while avoiding increased complexity, as the metabolic activators and antibiotics work synergistically in integrated formulations.
Data Source
AI summary
Disclosed herein are compounds, compositions, and methods for treating infections by bacteria and for killing bacteria. In particular, the disclosed compounds, compositions, and methods are useful for treating infections by bacteria and for killing persister bacteria that survive antibiotic treatment and then reconstitute infections.